American heart journal最新文献

{"title":"Response of health-related quality of life following pediatric/congenital cardiac catheterization procedures","authors":"Michael L. O'Byrne MD, MSCE ,&nbsp;Priya Sharma PhD ,&nbsp;Jing Huang PhD ,&nbsp;Christopher L. Smith MD, PhD ,&nbsp;Jie Tang MD ,&nbsp;Ryan Callahan MD ,&nbsp;Jonathan B. Edelson MD ,&nbsp;Yoav Dori MD, PhD ,&nbsp;Matthew J. Gillespie MD ,&nbsp;Jonathan J. Rome MD ,&nbsp;Andrew C. Glatz MD, MSCE","doi":"10.1016/j.ahj.2024.11.017","DOIUrl":"10.1016/j.ahj.2024.11.017","url":null,"abstract":"<div><h3>Background</h3><div>Health related quality of life (HRQOL) is a patient-reported metric (PRM) that provides a holistic measure of health that is not addressed in traditional outcome measures. The acute responsiveness of HRQOL after pediatric/congenital cardiac catheterization procedures has not, to our knowledge, been studied.</div></div><div><h3>Methods</h3><div>A single-center prospective cohort study was performed, longitudinally evaluating HRQOL and other PRM in school-age children and adolescents (ages 8-18) undergoing diagnostic and interventional cardiac catheterization procedures prior to their scheduled procedure, and then 1 day, ∼1 month, and ∼3 months after the procedure. Differences between HRQOL at baseline and at 1- and 3-month follow-up were evaluated using paired Student's t-tests.</div></div><div><h3>Results</h3><div>A total of 70 patient-parent/guardian dyads were studied. The participating patients were 13±3 years old, 51% female, and 74% non-Hispanic white, with 54% undergoing a diagnostic procedure. The trajectory of cardiac-specific HRQOL as measured through Pediatric Cardiac Quality of Life Inventory differed for patients undergoing diagnostic and interventional procedures. Following diagnostic procedures, there was no significant change in cardiac-specific HRQOL (<em>P</em> &gt; .05). After interventional procedures, patient-reported cardiac-specific HRQOL increased at both 1-month (4.3±11, <em>P</em> = .04) and 3-months (5.9±11.4, <em>P</em> = .02), though the same changes were not seen in parent/guardian-reported cardiac-specific HRQOL (<em>P</em> &gt; .05). PROMIS measures of physical function, psychological symptoms, and social function were associated with baseline cardiac-specific HRQOL (all <em>P</em> &lt; .05), but no associations were seen between other patient-reported outcomes and baseline HRQOL or change from baseline to 3-month follow-up.</div></div><div><h3>Conclusion</h3><div>Across a range of transcatheter interventional procedures, patient-reported cardiac-specific HRQOL improved in short term follow up, though these changes were not seen in parent/guardian reported measures. Incorporating these patient-centered metrics into evaluation of transcatheter therapies may provide more accurate measures of comparative effectiveness.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 71-83"},"PeriodicalIF":3.7,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142791007","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primary medication adherence in Medicare beneficiaries prescribed sacubitril-valsartan or renin-angiotensin system blockers for heart failure with reduced ejection fraction","authors":"Catherine S. Hwang MD, MSPH ,&nbsp;Rishi J. Desai PhD ,&nbsp;Aaron S. Kesselheim MD, JD, MPH ,&nbsp;Raisa Levin MS ,&nbsp;Benjamin N. Rome MD, MPH","doi":"10.1016/j.ahj.2024.11.015","DOIUrl":"10.1016/j.ahj.2024.11.015","url":null,"abstract":"<div><h3>Background</h3><div>Sacubitril-valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) that is now preferred over angiotensin-converting enzyme inhibitors (ACE-Is) and angiotensin-II-receptor blockers (ARBs) for treating heart failure with reduced ejection fraction (HFrEF). Primary medication adherence to a costly brand-name ARNI, compared to inexpensive generic ACE-Is or ARBs, is unknown.</div></div><div><h3>Methods</h3><div>This cohort study used a linked database of electronic health records and Medicare fee-for-service claims from a large integrated health care system in Boston to compare primary medication adherence among Medicare beneficiaries with HFrEF newly prescribed sacubitril-valsartan, those newly prescribed a generic ACE-I or ARB, and those switching from an ACE-I or ARB to sacubitril-valsartan. The primary outcome was the proportion of individuals who filled their first prescription for any ARNI, ACE-I, or ARB within 90 days; a secondary outcome was the mean number of days to first fill. We used logistic regression to adjust for variations in patient characteristics, including demographics, comorbidities, medication use, and qualification for subsidized out-of-pocket prescription drug costs.</div></div><div><h3>Results</h3><div>Among 50 new sacubitril-valsartan prescription recipients, 33 (66%) demonstrated primary adherence at 90 days, compared to 141 of 231 (61%) new ACE-I or ARB prescription recipients (adjusted odds ratio 1.32, 95% CI, 0.63-2.73, <em>P</em> = .51). The mean time to first fill was 18 days for those prescribed sacubitril-valsartan and 9 days for those prescribed generic ACE-Is or ARBs (<em>P</em> &lt; .001). By contrast, primary adherence at 90 days was higher (329 of 364, 90%) among those who switched from a generic ACE-I or ARB to newly prescribed sacubitril-valsartan.</div></div><div><h3>Conclusions</h3><div>In this small, single-center cohort study of Medicare beneficiaries with HFrEF, there was no difference in primary medication adherence among individuals newly prescribed sacubitril-valsartan and those newly prescribed generic ACE-Is or ARBs, although it took sacubitril-valsartan prescription recipients longer to fill their medication. Adherence was high among patients switching from an ACE-I or ARB to sacubitril-valsartan, suggesting that this switch was not associated with interruptions in renin-angiotensin blockade.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 84-91"},"PeriodicalIF":3.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Revenues, costs, and contribution margins of major inpatient cardiovascular procedures within the Medicare population","authors":"Kriyana P. Reddy BS ,&nbsp;Kaitlyn Shutlz MS ,&nbsp;Lauren A. Eberly MD, MPH ,&nbsp;Sameed Ahmed M. Khatana MD, MPH ,&nbsp;Alexander C. Fanaroff MD, MHS ,&nbsp;Guy David PhD ,&nbsp;David J. Cohen MD, MS ,&nbsp;Peter W. Groeneveld MD, MS ,&nbsp;Jay Giri MD, MPH ,&nbsp;Ashwin S. Nathan MD, MS","doi":"10.1016/j.ahj.2024.11.013","DOIUrl":"10.1016/j.ahj.2024.11.013","url":null,"abstract":"<div><h3>Introduction</h3><div>We sought to measure the revenues, costs, and contribution margins (CMs) for major inpatient cardiovascular procedures in the Medicare population in years 2016-2019, evaluate the differences in CMs across procedures, and identify temporal trends in CMs.</div></div><div><h3>Methods</h3><div>Claim-level costs were calculated using cost-to-charge ratios and subsequently Winsorized to adjust for outliers, and CMs were assessed as the difference between revenue and costs.</div></div><div><h3>Results and Discussion</h3><div>We found that revenues, costs, and CMs vary widely across major inpatient cardiovascular procedures and that rapidly proliferating cardiovascular procedures contribute sizeable net CMs to US hospitals.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 43-48"},"PeriodicalIF":3.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142779458","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and design of the PE-TRACT trial: A multicenter randomized trial to evaluate catheter-directed therapy for the treatment of intermediate-risk pulmonary embolism","authors":"Akhilesh K. Sista MD ,&nbsp;Andrea B. Troxel ScD ,&nbsp;Thaddeus Tarpey PhD ,&nbsp;Sameer Parpia PhD ,&nbsp;Samuel Z. Goldhaber MD ,&nbsp;William W. Stringer MD ,&nbsp;Elizabeth A. Magnuson ScD ,&nbsp;David J. Cohen MD, MSc ,&nbsp;Susan R. Kahn MD, MSc ,&nbsp;Sunil V. Rao MD ,&nbsp;Timothy A. Morris MD ,&nbsp;Keith S. Goldfeld DrPH ,&nbsp;Suresh Vedantham MD","doi":"10.1016/j.ahj.2024.11.016","DOIUrl":"10.1016/j.ahj.2024.11.016","url":null,"abstract":"<div><h3>Background</h3><div>The optimal management of patients with intermediate-risk pulmonary embolism (PE), who have right heart dysfunction (determined by a combination of imaging and cardiac biomarkers) but a normal blood pressure, is uncertain. These patients suffer from reduced functional capacity and a lower quality of life over the long-term, despite use of anticoagulant therapy. Catheter-directed therapy (CDT) is a promising treatment for acute PE that rapidly removes thrombus and potentially improves cardiac dysfunction. However, CDT has risk and is costly, and it is not known whether it improves long-term cardiorespiratory fitness and/or quality of life compared with anticoagulation alone.</div></div><div><h3>Methods</h3><div>We are therefore conducting an open-label, assessor-blinded, multicenter randomized trial, the Pulmonary Embolism: Thrombus Removal with Catheter-Directed Therapy (PE-TRACT) Study, to compare CDT plus anticoagulation (CDT group) with anticoagulation alone (No-CDT group) in 500 patients with intermediate-risk PE. The primary study hypothesis is that CDT will increase the peak oxygen uptake (peak VO₂) with cardiopulmonary exercise testing at 3 months and reduce New York Heart Association (NYHA) Class at 12 months compared with No-CDT. These 2 primary efficacy outcomes will be analyzed sequentially using a “gatekeeping” procedure; for NYHA class to be compared, peak oxygen consumption must first be shown to be significantly increased by CDT. Safety and cost-effectiveness will also be assessed.</div></div><div><h3>Conclusion</h3><div>When completed, PE-TRACT will provide important evidence regarding the benefits and risks of CDT to treat intermediate-risk PE compared with anticoagulation alone.</div></div><div><h3>Trial Registration</h3><div>clinicaltrials.gov: NCT05591118.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 112-122"},"PeriodicalIF":3.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783869","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Health status outcomes after acute myocardial infarction in patients without standard modifiable risk factors","authors":"Nobuhiro Ikemura MD, PhD ,&nbsp;Paul S. Chan MD, MSc ,&nbsp;Kensey Gosch MS ,&nbsp;Dan D. Nguyen MD, MS ,&nbsp;Charles F. Sherrod IV MD ,&nbsp;Mirza Khan MD, MS ,&nbsp;Yuan Lu ScD ,&nbsp;Mitsuaki Sawano MD, PhD ,&nbsp;Harlan M. Krumholz MD, SM ,&nbsp;John A. Spertus MD, MPH","doi":"10.1016/j.ahj.2024.11.018","DOIUrl":"10.1016/j.ahj.2024.11.018","url":null,"abstract":"<div><h3>Background</h3><div>Prior studies of patients presenting with acute myocardial infarction (AMI) without Standard Modifiable Risk Factors (SMuRFs), such as diabetes, dyslipidemia, hypertension, and smoking, reported higher in-hospital but lower long-term mortality than those with SMuRFs. However, the impact of SMuRFs on health status outcomes (patients’ symptoms, function, and quality of life) after a first AMI are unknown.</div></div><div><h3>Methods</h3><div>Data from 2 prospective registries, PREMIER and TRIUMPH, were used to identify patients with no prior history of coronary disease hospitalized at 31 U.S. hospitals for AMI between 2003 and 2008. Serial health status over 12 months was collected using the Seattle Angina Questionnaire (SAQ) Summary Score. Changes in SAQ over 12 months were compared between patients with and without SMuRFs using hierarchical linear mixed models with sequential adjustments for baseline SAQ scores, clinical, and sociodemographic characteristics.</div></div><div><h3>Results</h3><div>Among 4076 patients with a first AMI (mean age 58.4 ± 12.4, 34% female, 22% Black), 569 (14.0%) presented without SMuRFs. Compared with patients with SMuRFs, those without SMuRFs were more likely to be male, White, have higher income and education, fewer depressive symptoms, and higher baseline SAQ Summary Scores (83.5 ± 13.2 vs. 79.6 ± 16.5). After adjusting for baseline SAQ scores, patients without SMuRFs had larger SAQ Summary Score improvements at 12 months than those with SMuRFs (adjusted difference between groups = 2.61 points, 95% CI: 1.29-3.93), but sequential adjustment for clinical and socioeconomic characteristics attenuated this difference (1.69 points, 95% CI 0.40-1.97).</div></div><div><h3>Conclusions</h3><div>Among AMI patients, those without modifiable risk factors had similar health status at 12-months as compared with those having modifiable cardiovascular risk factors, which should provide reassurance to those with less targets for secondary prevention.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"281 ","pages":"Pages 123-132"},"PeriodicalIF":3.7,"publicationDate":"2024-12-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142783865","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Information for Readers","authors":"","doi":"10.1016/S0002-8703(24)00310-7","DOIUrl":"10.1016/S0002-8703(24)00310-7","url":null,"abstract":"","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"279 ","pages":"Page iv"},"PeriodicalIF":3.7,"publicationDate":"2024-12-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142759306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differences in Clinical Outcomes Between Non-Obese Caucasian and African American Populations Who Have Diabetes, A Nation-Wide Study","authors":"Sindhu Kishore M.D.,&nbsp;Leonid Khokhlov M.D.,&nbsp;Sila Mateo Faxas MD.,&nbsp;Mehwish Kishore M.D.,&nbsp;Kamal Shemisa M.D.","doi":"10.1016/j.ahj.2024.09.009","DOIUrl":"10.1016/j.ahj.2024.09.009","url":null,"abstract":"<div><div>DM is a metabolic disease that is closely linked with ethnicity. There is limited data on its outcomes in different racial groups. Controlling DM will mitigate the risks of atherosclerotic cardiovascular disease. The purpose of this study is to compare differences in clinical outcomes in non-obese Caucasian and African American (AA) populations with DM. Conducted as an observational study, it utilized data from the National Inpatient Sample from 2017 to 2020 focusing on non-obese adults over 18 years, with a BMI &lt;30 kg/m^2, and DM diagnosis, excluding those under 18, obese or without DM. Primary outcome was in-hospital mortality. Secondary outcomes were cardiogenic shock, cardiac arrest, GIB, mechanical ventilation, length of stay, and total cost. Multivariable logistic and Poisson regression analyses determined the clinical outcomes, considering a p-value &lt;0.05 significant. Among 22,300,000 non-obese adults with DM, 64.2% were Caucasians, 18.8% were AA, 13.3% were Hispanics, 3.5% were Asians, and the remaining population belonged to other ethnicities. This study revealed higher rates in the Caucasians for conditions like metabolic syndrome, dyslipidemia, HTN, A.fib, PVD, ACS, severe sepsis, and COPD. The AA were seen to have a higher incidence of anemia, DKA, pHTN, HF, AKI, CKD, stroke, and PE. In terms of the primary outcome, Caucasians had more in-hospital mortality than the AA, but the results were not statistically significant. Results for the secondary outcomes were variable as seen in Table 1. The findings undermine the importance of racial differences in such conditions and more in-depth studies are needed to extrapolate the gaps in care.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 1"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143100422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obicetrapib Demonstrates Significant Deductions of LP(A) on Top of High-Intensity Statins","authors":"S. Tsimikas,&nbsp;X. Yang,&nbsp;A. Hsieh,&nbsp;M. Ditmarsch,&nbsp;M. Davidson,&nbsp;J. Kastelein","doi":"10.1016/j.ahj.2024.09.013","DOIUrl":"10.1016/j.ahj.2024.09.013","url":null,"abstract":"<div><div><strong>Background and Aims:</strong> Elevated lipoprotein (a) [Lp(a)] leads to increased cardiovascular disease (CVD) risk. There are no pharmacologic therapies approved for reducing Lp(a). Previous cholesteryl ester transfer protein (CETP) inhibitors and approved lipid agents have modest Lp(a) effects. We examined the effects of obicetrapib, a novel CETP inhibitor, on Lp(a).</div><div><strong>Methods:</strong> ROSE1 and ROSE2 are phase 2 trials of obicetrapib on top of high-intensity statins by persons without CVD and low-density lipoprotein cholesterol &gt;70 mg/dL. In ROSE1 120 subjects received 5 or 10 mg obicetrapib or placebo; in ROSE2 119 received 10 mg obicetrapib, 10 mg obicetrapib + 10 mg ezetimibe or placebo. Lp(a) was measured by immunoturbidimetry in ROSE1 and by the UCSD isoform independent assay using monoclonal antibody LPA-KIV9 in ROSE2.</div><div><strong>Results:</strong> Median baseline Lp(a) for 10 mg obicetrapib and placebo was 29.9 and 45.3 nmol/L in ROSE1 and 44.0 and 37.8 nmol/L in ROSE2, respectively. Median % changes from baseline for obicetrapib 10 mg and placebo, respectively, were -56.5 and +4.00 in ROSE1 and -47.2 and +2.3 in ROSE2. Pooled (N=127) median difference in % change corrected for placebo was 57.1% (p&lt;0.001). In both trials &gt;50% of obicetrapib subjects had a &gt;60% reduction in Lp(a).</div><div><strong>Conclusions:</strong> Obicetrapib 10 mg on top of high-intensity statin significantly lowered Lp(a) by 57% vs. placebo in a pooled analysis, a substantially greater reduction than with proprotein convertase subtilisin kexin type 9 inhibitors (15-30%), niacin (30%) or other CETP inhibitors (25%).</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 3"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-Human Primates","authors":"J. Kastelein,&nbsp;M. Ditmarsch,&nbsp;A. Hsieh,&nbsp;M. Dicklin,&nbsp;M. Davidson","doi":"10.1016/j.ahj.2024.09.015","DOIUrl":"10.1016/j.ahj.2024.09.015","url":null,"abstract":"<div><div><strong>Background and Aims:</strong> Previous CETP inhibitors were highly lipophilic with logP of 7.2–9.2, leading to adipose tissue accumulation in the case of anacetrapib. In contrast, obicetrapib is characterized by a logP of 4.9 and terminal half-life of ∼135 hours. Studies in monkeys and humans were undertaken to determine the definitive elimination of obicetrapib.</div><div><strong>Methods:</strong> Obicetrapib was administered at doses up to 50 mg/kg/day in cynomolgus monkeys. A phase 1 trial administered doses of 1-25 mg to healthy humans, and 3 placebo-controlled, phase 2 studies in dyslipidemic humans administered obicetrapib (on background statin therapy) at 5 or 10 mg/d for 8 weeks (ROSE; n=120), 10 mg/d monotherapy or with ezetimibe for 12 weeks (ROSE2; n=119), and 2.5, 5, or 10 mg/d for 8 weeks (Japan; n=102). Plasma concentrations of obicetrapib were measured during the studies and post-treatment.</div><div><strong>Results:</strong> In monkeys, obicetrapib was not detected in any adipose tissue. A period of 13 weeks was sufficient for complete elimination from systemic circulation. The terminal half-life of obicetrapib was 121-151 hours in healthy humans. Across phase 3 studies, the median plasma concentration of obicetrapib reached 384-472 μg/L and decreased by up to 93-99% by 4 to 15 weeks post-treatment.</div><div><strong>Conclusions:</strong> Obicetrapib shows no evidence of accumulation in adipose tissue or delayed elimination from the systemic circulation supporting once daily, chronic dosing of 10 mg.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Page 4"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156759","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medical Treatment of Hypercortisolism with Relacorilant: Final Results of the Phase 3 GRACE Study","authors":"Rosario Pivonello ,&nbsp;Giorgio Arnaldi ,&nbsp;J. Richard Auchus ,&nbsp;Corin Badiu ,&nbsp;Robert S. Busch ,&nbsp;Salvatore Cannavo ,&nbsp;Ulrich Dischinger ,&nbsp;Georgiana A. Dobri ,&nbsp;Diane Donegan ,&nbsp;Atanaska Elenkova ,&nbsp;Pouneh K. Fazeli ,&nbsp;Richard A. Feelders ,&nbsp;Rogelio Garcia-Centeno ,&nbsp;Aleksandra Gilis-Januszewska ,&nbsp;Oksana Hamidi ,&nbsp;Zeina C. Hannoush ,&nbsp;Harold J. Miller ,&nbsp;Aurelian-Emil Ranetti ,&nbsp;Monica Recasens ,&nbsp;Martin Reincke ,&nbsp;Andreas G. Moraitis","doi":"10.1016/j.ahj.2024.09.027","DOIUrl":"10.1016/j.ahj.2024.09.027","url":null,"abstract":"<div><div>Diabetic cardiomyopathy (DCM) is a cardiometabolic syndrome, manifested by ventricular diastolic or systolic dysfunction which occurs in approximately 12% of diabetic patients. Diabetes perpetuates the development of microvascular complications that can exacerbate cardiovascular pathologies. Understanding the common molecular targets underlying these two conditions is important for designing effective interventions that can address diabetes and related complications simultaneously. Herein, we aim to investigate the underlying network of key modules associated with diabetic cardiomyopathy. In current study, microarray gene expression profiles of diabetic and cardiomyopathy patients possessing accession number (GSE30122 and GSE20966) and (GSE89714, GSE3586, and GSE1145) were retrieved from Gene Expression Omnibus (GEO) database to explore key modulators. The differentially expressed genes (DEGs) were analyzed via GEO2R tool, based on the cut off criteria (p ≤ 0.05) and log2(FC)&gt;|±1|. 37 overlapped DEGs were identified which then subjected to miRNA target prediction, protein-protein interaction (PPI) network construction and module screening via TargetScan, ShinyGO, STRING, and Cytoscape respectively, to screen hub genes as potential targets. Functional gene enrichment analysis identified enrichment of DEGs in heart contraction, apoptosis, cytokines signaling, beta adrenergic signaling and GPCR neurotransmitter receptor activity. The miRNA-mRNA regulatory network identified 9 hub genes, including ADRB1, TGFB2, RAP2A, CALD1, WIPF1, ATP10a, AKAP1, NR4A3, EXT1 and 4 hub miRNAs including miR-199-5, miR-200a, mir141-3, and miR-19-3p based on their degree of connectivity and centrality within the network. Conclusively, our analysis unveiled hub genes and miRNAs associated with diabetes-linked cardiomyopathy that might considered as biomarkers and offer a reliable tool for developing effective therapeutic strategies in future.</div></div>","PeriodicalId":7868,"journal":{"name":"American heart journal","volume":"278 ","pages":"Pages 10-11"},"PeriodicalIF":3.7,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143156770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}